ISSN (print) 1726-9806     ISSN (online) 1818-474X
No. 3 (2020), DIAGNOSTICS AND INTENSIVE CARE IN DISEASES OF NERVOUS SYSTEM
No. 3 (2020)
DIAGNOSTICS AND INTENSIVE CARE IN DISEASES OF NERVOUS SYSTEM

Blood-brain barrier from the point of view of anesthesiologist. Review. Part 1

Published 02.09.2020
Vladimir I. Gorbachev
ISMAPgE — Branch Campus of the FSBEI FPE RMACPE MOH Russia
https://orcid.org/0000-0001-6278-9332
N.V. Bragina
ISMAPgE — Branch Campus of the FSBEI FPE RMACPE MOH Russia
https://orcid.org/0000-0001-6131-8184
#2020-3
PDF_2020-03_35-45 (Russian)
HTML_2020-03_35-45 (Russian)

Keywords

blood-brain barrier
neurovascular unit
blood-cerebrospinal fluid barrier
intrathecal administration of drugs
cerebrospinal fluid

How to Cite

1.
Gorbachev V.I., Bragina N.V. Blood-brain barrier from the point of view of anesthesiologist. Review. Part 1. Annals of Critical Care. 2020;(3):35-45. doi:10.21320/1818-474X-2020-3-35-45
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistic

Abstract Views: 802
PDF_2020-03_35-45 (Russian) Downloads: 354
HTML_2020-03_35-45 (Russian) Downloads: 2206
Statistic from 01.07.2024

Language

English Русский

Most reader

Social Networks

Abstract

The blood-brain barrier prevents the penetration of neurotoxic components of plasma, blood cells and pathogens into the brain. At the same time, it regulates the transport of molecules in the central nervous system, maintaining a strictly controlled chemical composition of the neuronal environment. This review discusses the molecular and cellular mechanisms that underlie the functioning of the blood-brain barrier, the physiology of the blood-brain barrier transport systems, the structural components of the blood-cerebrospinal fluid barrier and the intrathecal administration of drugs. Based on the physicochemical properties of antibacterial drugs, we estimated which compounds are currently the most promising for the treatment of infections of the central nervous system.
PDF_2020-03_35-45 (Russian)
HTML_2020-03_35-45 (Russian)

References

  1. Erdő F., Denes L., de Lange E. Age-associated physiological and pathological changes at the blood-brain barrier: A review. J. Cerebral Blood Flow &Metabolism. 2017; 37(1): 4–24. DOI: 10.1177/0271678X16679420
  2. Dalvi S., On N., Nguyen H., et al. The Blood Brain Barrier — Regulation of Fatty Acid and Drug Transport. Neurochemistry. 2014; 1–33. DOI: 10.5772/57604
  3. Моргун А.В., Кувачева Н.В., Комлева Ю.К. и др. Модели гематоэнцефалического барьера in vitro: современное состояние проблемы и перспективы. Анналы клинической и экспериментальной неврологии. 2012; 6(4): 42–51. [Morgun A.V., Kuvacheva N.V., Komleva Ju.K., et al. Modeli gematoencefalicheskogo bar’era in vitro: sovremennoe sostoyanie problemy i perspektivy. Annaly klinicheskoj i jeksperimental’noj nevrologii. 2012; 6(4):42–51. (In Russ)]
  4. Чехонин В.П., Баклаушев В.П., Юсубалиева Г.М. и др. Фундаментальные и прикладные аспекты изучения гематоэнцефалического барьера. Вестник Российской академии медицинских наук. 2012; 8: 66–78. [Chehonin V.P., Baklaushev V.P., Jusubalieva G.M., et al. Fundamental’nye i prikladnye aspekty izucheniya gematoencefalicheskogo bar’era. Vestnik Rossijskoj akademii medicinskih nauk. 2012; 8: 66–78. (In Russ)]
  5. Пикалюк В.С., Корсунская Л.Л., Роменский А.О., Шаймарданова Л.Р. Циркумвентрикулярная система как «ворота» в головной мозг. Таврический медико-биологический вестник. 2013; 16(1–1): 270–275. [Pikaljuk V.S., Korsunskaja L.L., Romenskij A.O., Shajmardanova L.R. Cirkumventrikulyarnaya sistema kak “vorota” v golovnoj mozg. Tavricheskij mediko-biologicheskij vestnik. 2013; 16(1–1): 270–275. (In Russ)]
  6. Lu C., Zhao Y., Wong H.L., et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int. J. Nanomedicine. 2014; 9: 2241–2257. DOI: 10.2147/IJN.S61288
  7. Блинов Д.В. Современные представления о роли нарушения резистентности гематоэнцефалического барьера в патогенезе заболеваний ЦНС. Часть 2: функции и механизмы повреждения гематоэнцефалического барьера. Эпилепсия и пароксизмальные состояния. 2014; 6(1):70–84. [Blinov D.V. Sovremennye predstavleniya o roli narusheniya rezistentnosti gematoencefalicheskogo bar’era v patogeneze zabolevanij CNS. CHast’ 2: funkcii i mekhanizmy povrezhdeniya gematoencefalicheskogo bar’era. Jepilepsija i paroksizmal’nye sostojanija. 2014; 6(1): 70–84. (In Russ)]
  8. Weiss N., Miller F., Cazaubon S., Couraud P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta. 2009; 1788: 842–857. DOI: 10.1016/j.bbamem.2008.10.022
  9. Warren K.E. Beyond the blood-brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Frontiers in Oncology. 2018; 8: 239. DOI: 10.3389/fonc.2018.00239
  10. Горбачев В.И., Маньков А.В., Христенко И.В., Капустина А.В. О некоторых механизмах гомеостаза центральной нервной системы. Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук. 2006; 5(51): 52–55. [Gorbachev V.I., Man‘kov A.V., Hristenko I.V., Kapustina A.V. O nekotoryh mekhanizmah gomeostaza central’noj nervnoj sistemy. Bjulleten’ Vostochno-Sibirskogo nauchnogo centra Sibirskogo otdelenija Rossijskoj akademii medicinskih nauk. 2006; 5(51): 52–55. (In Russ)]
  11. Nau R., Sörgel F., Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews. 2010; 23(4): 858–883. DOI: 10.1128/CMR.00007-10
  12. Cabrera-Maqueda J.M., Rumí L.F., López G.V., et al. Antibiotic diffusion to central nervous system. Revista Espanola de Quimioterapia. 2018; 31(1): 1–12. (In Spain)
  13. Djukic M., Munz M., Sörgel F., et al. Overton’s rule helps to estimate the penetration of anti-infectives into patients’ cerebrospinal fluid. Antimicrobial Agents Chemotherapy. 2012; 56(2): 979–988. DOI: 10.1128/AAC.00437-11
  14. Flierl M.A., Stahel P.F., Rittirsch D., et al. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Critical Care. 2009; 13: 12. DOI: 10.1186/cc7710
  15. Hofer S., Bopp C., Hoerner C., et al. Injury of the blood brain barrier and up-regulation of icam-1 in polymicrobial sepsis. J. Surgical Research. 2008; 146: 276–28. DOI: 10.1016 / j.jss.2007.07.021
  16. Viladrich P.F., Cabellos C., Pallares R., et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy. 1996; 40(1): 218–220. DOI: 10.1128/AAC.40.1.218
  17. Wong V.K., Wright H.T., Ross L.A.Jr., et al. Imipenem/cilastatin treatment of bacterial meningitis in children. The Pediatric Infectious Disease Journal. 1991; 10: 122–125.
  18. De Sarro A., Ammendola D., Zappala M., et al. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrobial Agents and Chemotherapy. 1995; 39: 232–237.
  19. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice Guidelines for the Management of Bacterial Meningitis. Clinical Infectious Diseases. 2004; 39(9): 1267–1284. DOI: 10.1086/425368
  20. Cawley M.J., Suh C., Lee S., Ackerman B.H. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy. 2002; 22: 527–532.
  21. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clinical pharmacokinetics. 1997; 33: 52–77.
  22. Лебедев И.А., Левитина Е.В., Акимжанова А.К. и др. Интратекальное введение лекарственных препаратов. Журнал неврологии и психиатрии. 2016; 10,89–92. DOI: 10.17116/jnevro201611610189-92 [Lebedev I.A., Levitina E.V., Akimzhanova A.K., et al. Intratekal’noe vvedenie lekarstvennyh preparatov. Zhurnal nevrologii i psihiatrii. 2016; 10: 89–92. (In Russ)]
  23. Потапов А.А., Крылов В.В., Гаврилов А.Г. и др. Рекомендации по диагностике и лечению тяжелой черепно-мозговой травмы. Часть 2. Интенсивная терапия и нейромониторинг. Вопросы нейрохирургии. 2016; 1: 98–106. DOI: 10.17116/neiro201680198-106 [Potapov A.A., Krylov V.V., Gavrilov A.G., et al. Rekomendacii po diagnostike i lecheniyu tyazheloj cherepno-mozgovoj travmy. CHast’ 2. Intensivnaya terapiya i nejromonitoring. Voprosy nejrohirurgii. 2016; 1: 98–106. (In Russ)]
  24. Nau R., Blei C., Eiffert H. Intrathecal antibacterial and antifungal therapies. Clinical Microbiology Reviews. 2020; 33(3): 00190–19. DOI: 10.1128/CMR.00190-19.
  25. Агаркова А.А., Покровский М.В., Корокина Л.В., Землянский О.А. Пневмококковый менингит: современные аспекты диагностики и лечения. Клиническая фармакология и терапия. 2019; 28(2): 84–92. DOI: 10.32756/0869-5490-2019-2-84-92 [Agarkova A.A., Pokrovskii M.V., Korokina L.V., Zemlyanskii O.A. Pnevmokokkovyj meningit: sovremennye aspekty diagnostiki i lecheniya. Klinicheskaya farmakologiya i terapiya. 2019; 28(2): 84–92. (In Russ)]
  26. Van de Beek D., Cabellos C., Dzupova O., et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2016; 22: 37–62. DOI: 10.1016/j.cmi.2016.01.007.
  27. Edwards R.J., Drake J.M. Cerebrospinal fluid devices. Youmans & Winn Neurological Surgery. 7th ed. 2017: 1638–1643.
  28. Карпов И.А., Шанько Ю.Г., Соловей Н.В. и др. Менингиты и вентрикулиты, связанные с оказанием медицинской помощи: диагностика, лечение и профилактика. Клиническая микробиология и антимикробная химиотерапия. 2018; 20(4): 260–288. Режим доступа: https://cyberleninka.ru/article/n/meningity-i-ventrikulity-svyazannye-s-okazaniem-meditsinskoy-pomoschi-diagnostika-lechenie-i-profilaktika. Ссылка активна на 02.05.2020. [Karpov I.A., Shan‘ko Yu.G., Solovei N.V., et al. Meningity i ventrikulity, svyazannye s okazaniem medicinskoj pomoshchi: diagnostika, lechenie i profilaktika. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2018; 20(4): 260–288. Available at: https://cyberleninka.ru/article/n/meningity-i-ventrikulity-svyazannye-s-okazaniem-meditsinskoy-pomoschi-diagnostika-lechenie-i-profilaktika. Accessed: 02.05.2020. (In Russ)]
  29. Потапов А.А., Крылов В.В., Лихтерман Л.Б. и др. Клинические рекомендации по лечению пострадаших с тяжелой черепно-мозговой травмой. М., 2014: 21. [Potapov A.A., Krylov V.V., Likhterman L.B., et al. Klinicheskie rekomendacii po lecheniyu postradashih s tyazheloj cherepno-mozgovoj travmoj. M., 2014: 21. (In Russ)]
  30. Khan S.A., Waqas M., Siddiqui U.T., et al. Intrathecal and intraventricular antibiotics for postoperative Gram-negative meningitis and ventriculitis. Surgical Neurology International. 2017; 8: 226. DOI: 10.4103/sni.sni_81_17
  31. Lich B.F., Conner A.K., Burks J.D., et al. Intrathecal/intraventricular linezolid in multidrug-resistant Enterococcus faecalis ventriculitis. J. Neurological Surgery Reports. 2016; 77(04): 160–161. DOI: 10.1055 / s-0036-1593439
  32. Wang H., Zhao S., Chen B., et al. Comparison of the curative efficacy of intrathecal and intravenous injection of ceftriaxone and vancomycin in the treatment of intracranial infection during the perioperative period. International journal of clinical and experimental medicine. 2017; 10(11): 15485–15491.
  33. Mader M.M., Czorlich P., König C., et al. Intrathecal penetration of meropenem and vancomycin administered by continuous infusion in patients suffering from ventriculitis — a retrospective analysis. Acta Neurochirurgica. 2018; 160: 2099–2105. DOI: 10.1007/s00701-018-3680-z
  34. Zhang Q., Chen H., Zhu C., et al. Efficacy and safety of intrathecal meropenem and vancomycin in the treatment of postoperative intracranial infection in patients with severe traumatic brain injury. Experimental and Therapeutic Medicine. 2019; 17: 4605–4609. DOI: 10.3892 / etm.2019.7503.
  35. Ziai W.C., Lewin J.J. Improving the role of intraventricular antimicrobialagents in the management of meningitis. Current opinion in neurology. 2009; 22: 277–282. DOI: 10.1097/WCO.0b013e32832c1396
  36. Tunkel A.R., Hasbun R., Bhimraj A., et al. Infectious diseases society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clinical Infectious Diseases. 2017; 64(6): 34–65. DOI: 10.1093/cid/ciw861
  37. McCracken G.H., Mize S.G.Jr., Threlkeld N. Intraventricular gentamicin therapy in Gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet. 1980; 1: 787–791.
  38. Shah S.S., Ohlsson A., Shah V.S. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database of Systematic Reviews. 2004; 4: CD004496. DOI: 10.1002/14651858.CD004496.pub2
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

<< < 1 2